QureBio Ltd. Reveals Q-1802 Phase II Results at ASCO 2026 Conference QureBio Ltd. presented promising Phase II clinical data for its bispecific antibody Q-1802 at ASCO 2026, indicating strong efficacy and manageable safety.

QureBio Ltd. Reveals Q-1802 Phase II Results at ASCO 2026 Conference #China #Shanghai #QureBio #Q-1802 #ASCO_2026